News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Less Than Two Weeks Remain before Deadline in Class-Action Lawsuit Against Dendreon Corporation, Says Hagens Berman
September 22, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SEATTLE--(BUSINESS WIRE)--Hagens Berman Sobol Shapiro LLP reminds investors that those who wish to serve as lead plaintiff in a class-action lawsuit against Dendreon (NASDAQ:DNDN) have less than two weeks from today to file their motion.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
Policy
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
October 23, 2026
·
2 min read
·
Nick Paul Taylor
Job Trends
As H-1B visa changes keep coming, biopharmas adjust hiring approach
October 22, 2026
·
5 min read
·
Angela Gabriel
Legal
‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban
October 14, 2026
·
4 min read
·
Annalee Armstrong
Manufacturing
Merck barred from making subcutaneous Keytruda in 8 European countries
October 8, 2026
·
2 min read
·
Nick Paul Taylor